Nutriband Inc. Warrant (NASDAQ:NTRBW)
| Market Cap | 133.08M-50.3% |
| Revenue (ttm) | 1.62M-37.3% |
| Net Income | -6.96M+32.2% |
| EPS | -0.57+80.1% |
| Shares Out | 11.94M |
| PE Ratio | n/a |
| Forward PE | 0.27 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,066 |
| Open | 2.61 |
| Previous Close | 0.39 |
| Day's Range | 0.54 - 2.61 |
| 52-Week Range | 0.17 - 2.99 |
| Beta | 1.97 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 30, 2026 |
About NTRBW
Nutriband Inc. is a pharmaceutical company dedicated to advancing a diverse pipeline of transdermal drug products. Foremost among its developmental initiatives is an abuse-deterrent fentanyl transdermal system. This innovative patch aims to provide both healthcare providers and patients with an extended-release fentanyl solution for the effective management of chronic pain. Beyond its core transdermal portfolio, Nutriband Inc. also holds a licensing agreement with Rambam Med-Tech Ltd. for the development of RAMBAM Closed System Transfer Devices. Established in 2016, the company maintains its corporate headquarters in Orlando, Florida.
$NTRBW stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in NTRBW holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NTRBW's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NTRBW Estimated quarterly lobbying spending
Source: U.S. Senate LDA
NTRBW Revenue by Segment or Geography
Source: SEC EDGAR (10-Q/10-K)
U.S. Patents
New NTRBW patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NTRBW from public contracts
Source: USAspending.gov
NTRBW Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from NTRBW’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.